Physician profile
Amber Jack
NPI 1992445951
$1,877.21
in general payments reported to CMS, 2019-2025
14 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $147 · 2023: $226 · 2024: $375 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $680.78 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $442.78 | 2023-2025 | |
| Amgen INC. | $238.93 | 2022-2024 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2025 | Caplyta |
| Exact Sciences Corporation | $115.67 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $83.56 | 2023-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $38.20 | 2024-2025 | |
| Boston Scientific Corporation | $33.77 | 2025 | Watchman Flx |
| Merck Sharp & Dohme LLC | $32.27 | 2022 | |
| Glaxosmithkline, LLC. | $26.32 | 2023 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $16.20 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.15 | 2025 | Zoryve |
| Novo Nordisk INC | $14.45 | 2024 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $13.13 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Jack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.